SC
VKTX icon

Shay Capital’s Viking Therapeutics VKTX Stock Holding History

Shay Capital’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,500
Closed -$533K – 650
2026
Q1 		$537K Buy
+16,500
New +$530K 0.04% 262
2025
Q3 		– Sell
-12,100
Closed -$361K – 512
2025
Q2 		$321K Sell
12,100
-900
-7% -$23.7K 0.04% 219
2025
Q1 		$314K Sell
13,000
-39,500
-75% -$1.25M 0.05% 192
2024
Q4 		$2.11M Buy
52,500
+18,134
+53% +$1.03M 0.32% 74
2024
Q3 		$2.18M Sell
34,366
-12,734
-27% -$747K 0.31% 51
2024
Q2 		$2.5M Buy
47,100
+20,800
+79% +$1.36M 0.34% 52
2024
Q1 		$2.16M Buy
+26,300
New +$1.17M 0.34% 52
2023
Q3 		– Sell
-11,000
Closed -$178K – 503
2023
Q2 		$178K Buy
+11,000
New +$230K 0.02% 298

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Shay Capital's VKTX Position: Q2 2026 in Review

Shay Capital sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 16,500 shares — an estimated $533K sold.

Shay Capital first reported a position in VKTX in Q2 2023 and held it in 8 quarters. The position peaked at $2.5M in Q2 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Shay Capital reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Shay Capital sold 16,500 Viking Therapeutics shares in Q2 2026, an estimated $533K.
  • Shay Capital first reported a position in Viking Therapeutics in Q2 2023 and held it in 8 quarters.
  • Shay Capital's Viking Therapeutics position peaked at $2.5M in Q2 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Shay Capital's 13F filing for Q2 2026, filed 14 Aug 2026.